The inverse association of incident cardiovascular disease with plasma bilirubin is unaffected by adiponectin

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 380-383

  Dullaart, Robin P F ^a   Boersema, Jeltje ^a   Lefrandt, Joop D ^a   Wolffenbuttel, Bruce H R ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adiponectin; Bilirubin; Cardiovascular disease; Prospective nested case control study

Indexed keywords

ADIPONECTIN; BILIRUBIN;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN INTERACTION; AGED; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; INCIDENCE; MIDDLE AGED; RISK FACTOR;

ADIPONECTIN; ADULT; AGED; BILIRUBIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84908648821     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.938     Document Type: Article

References (29)

1. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
2. Neuzil J., Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. JBiol Chem 1994, 269:16712-16719.
3. Mazzone G.L., Rigato I., Ostrow J.D., Bossi F., Bortoluzzi A., Sukowati C.H., Tedesco F., Tiribelli C. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009, 386:338-344.
4. Abraham N.G., Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 2005, 39:1-25.
5. Vítek L., Schwertner H.A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007, 43:1-57.
6. Lin J.P., Vítek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010, 56:1535-1543.
7. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 2012, 3:55.
8. McCarty M.F. Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues - a rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 2013, 81:607-610.
9. Novotný L., Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med 2003, 228:568-571.
10. Ajja R., Lee D.C., Sui X., Church T.S., Steven N.B. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol 2011, 15(108):1438-1442.
11. Erdogan D., Gullu H., Yildirim E., Tok D., Kirbas I., Ciftci O., Baycan S.T., Muderrisoglu H. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006, 184:431-437.
12. Vítek L., Novotný L., Sperl M., Holaj R., Spácil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006, 21:408-414.
13. Dullaart R.P.F., Kappelle P.J.W.H., de Vries R. Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and type 2 diabetic subjects. Clin Chim Acta 2012, 414:161-165.
14. Chan K.H., O'Connell R.L., Sullivan D.R., Hoffmann L.S., Rajamani K., Whiting M., Donoghoe M.W., Vanhala M., Hamer A., Yu B., Stocker R., Ng M.K., Keech A.C., FIELD Study Investigators Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2013, 56:724-736.
15. Lin H., Yu C.H., Jen C.Y., Cheng C.F., Chou Y., Chang C.C., Juan S.H. Adiponectin-mediated heme oxygenase-1 induction protects against iron-induced liver injury via a PPARα dependent mechanism. Am J Pathol 2010, 177:1697-1709.
16. Li M., Kim D.H., Tsenovoy P.L., Peterson S.J., Rezzani R., Rodella L.F., Aronow W.S., Ikehara S., Abraham N.G. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008, 57:1526-1535.
17. Vanella L., Li Volti G., Guccione S., Rappazzo G., Salvo E., Pappalardo M., Forte S., Schwartzman M.L., Abraham N.G. Heme oxygenase-2/adiponectin protein-protein interaction in metabolic syndrome. Biochem Biophys Res Commun 2013, 432:606-611.
18. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., Danesh J., Whincup P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
19. Dallinga-Thie G.M., Dullaart R.P.F. Do genome-wide association scans provide additional information on the variation of plasma adiponectin concentrations?. Atherosclerosis 2010, 208:328-329.
20. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., de Jong P.E., Wolffenbuttel B.H.R., Grobbee D.E., van Tol A., Dullaart R.P.F., PREVEND Study Group High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007, 28:1012-1018.
21. Dullaart R.P.F., Perton F., van der Klauw M.M., Hillege H.L., Sluiter W.J. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010, 208:537-542.
22. Miettinen O.S. Design of sampling from the base. Theoretical epidemiology 1985, 69-83. John Wiley & Sons, New York. O.S. Miettinen (Ed.).
23. Tisdale W.A., Klatskin G., Kinsella E.D. The significance of the direct-reacting fraction of serum bilirubin in hemolytic jaundice. Am J Med 1959, 26:214-227.
24. Deetman P.E., Kwakernaak A.J., Bakker S.J., Dullaart R.P.F. Low-normal free thyroxine confers decreased serum bilirubin in type 2 diabetes mellitus. Thyroid 2013, 23:1367-1373.
25. Selvin S. Statistical analysis of epidemiological data 1996, Oxford University Press, New York.
26. Lu M., Lyden P.D., Brott T.G., Hamilton S., Broderick J.P., Grotta J.C. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. JNeurosci Methods 2005, 143:209-216.
27. Dastani Z., Johnson T., Kronenberg F., Nelson C.P., Assimes T.L., März W., CARDIoGRAM Consortium, ADIPOGen Consortium, Richards J.B. The shared allelic architecture of adiponectin levels and coronary artery disease. Atherosclerosis 2013, 229:145-148.
28. Kim D.H., Burgess A.P., Li M., Tsenovoy P.L., Addabbo F., McClung J.A., Puri N., Abraham N.G. Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. JPharmacol Exp Ther 2008, 325:833-840.
29. Salman T.A., Allam N., Azab G.I., Shaarawy A.A., Hassouna M.M., El-Haddad O.M. Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int 2010, 4:767-774.